Ascendis Pharma A/S reported €720M of revenue over the trailing twelve months, +98% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €720M (to Q4 2025). Net income: −€228M, trailing twelve months to Q4 2025. Operating margin: −32%, trailing twelve months to Q4 2025. EPS: −€3.83, trailing twelve months to Q3 2025.

ASNDAscendis Pharma A/S

Healthcare

$229.11+16% 1Y

$229.11

$189.7452 weeks$271.13

ASND as reported

Ascendis Pharma A/S reported €720M of revenue over the trailing twelve months, +98% on the year before. 10 reported series are charted on this page, each one as filed.

€720M

Revenue, trailing twelve months · to Q4 2025 · +98% against the twelve months before

Net income: −€228M
Net income · −40% year on year · trailing twelve months to Q4 2025
Operating margin: −32%
Operating margin · trailing twelve months to Q4 2025
EPS: −€3.83
EPS · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for ASND, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€720M	+98%	Q4 2025
Net income	−€228M	−40%	Q4 2025
EPS	−€3.83	n/a	Q3 2025
Gross margin	86%	n/a	Q4 2025
Operating margin	−32%	n/a	Q4 2025
Net margin	−40%	n/a	Q4 2025
ROE	150%	n/a	Q4 2025
ROA	−24%	n/a	Q4 2025
ROIC	−282%	n/a	Q4 2025
Free cash flow	−€308M	n/a	Q4 2024 · 4 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.